FDA accepts Northera resubmission

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) said FDA accepted for review a resubmitted NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH) in patients wi...